





































Effect of statin treatment in patients with acute
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Abstract
Studies comparing long-term clinical outcomes of statin treatment between acute myocardial infarction (AMI) patients with
prediabetes and those with type 2 diabetes mellitus (T2DM) after successful percutaneous coronary intervention (PCI) with the
newer-generation drug-eluting stents (DESs) are limited. We compared 2-year clinical outcomes between these patients.
A total of 11,962 AMI patients were classified as statin users (n=10,243) and statin nonusers (n=1719). Thereafter, statin users
and nonusers were further divided into the normoglycemia, prediabetes, and T2DM groups. The major outcome was the occurrence
of major adverse cardiac event (MACE) defined as all-cause death, recurrent myocardial infarction (Re-MI), or any repeat coronary
revascularization.
After statin treatment, the cumulative incidences of MACE (P= .314), all-cause death, cardiac death (CD), Re-MI, and any repeat
revascularization were similar between the prediabetes and T2DM groups. However, the cumulative incidences of MACE (P= .025)
and all-cause death (P= .038) in the prediabetes group and those of MACE (P= .001), all-cause death (P= .009), and CD (P= .048) in
the T2DM group were significantly higher than those in the normoglycemia group. Moreover, in all the 3 glycemic groups, the
cumulative incidences of MACE, all-cause death, and CD were significantly higher among statin nonusers than among statin users.
This study revealed that AMI patients with prediabetes had worse clinical outcomes than those with normoglycemia and
comparable to those with T2DM after 2-year statin treatment. However, further studies are warranted to confirm the current findings.
Abbreviations: AMI = acute myocardial infarction, DES = drug-eluting stents, KAMIR = Korea Acute Myocardial Infarction
Registry, MACE =major adverse cardiac events, PCI= percutaneous coronary intervention, Re-MI= recurrent myocardial infarction,
T2DM = type 2 diabetes mellitus.
Keywords: diabetes, myocardial infarction, outcomes, prediabetes, statin
1. Introduction
Patients with diabetesmellitus (DM) have a two-fold higher risk of
cardiovascular death than those without DM.[1] Huang et al[2]
reported that compared with normoglycemia, prediabetes was
associatedwith an increased risk of coronary heart disease (relative
risk [RR]: 1.10). According to recent reports,[3,4] the risk profile for
major clinical endpoints after contemporary drug-eluting stent
(DES) placementmay be comparable between prediabetic andDM
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patients. By contrast, some reports[5,6] have demonstrated that the
mortality rate is higher inDMpatients than in prediabetic patients.
However, despite these conflicting findings, approximately two-
thirds of acute myocardial infarction (AMI) patients have diabetes
or prediabetes.[7] Aspirin, statin, renin–angiotensin system
inhibitors (RASIs), and beta-blockers (BBs) have been shown to
significantly reduce mortality following AMI in patients with and
without DM.[8–11] Moreover, in a large meta-analysis,[12] statin
treatment showed a 9% proportional reduction in all-cause
mortality (P= .02) in patients with established DM. However, in
prediabetic patients, intensive lifestyle modifications and metfor-
min therapyare theonlyuniversally accepted interventions forDM
prevention.[13] In real-world practice, statin is prescribed to all
AMI patients without contraindications to statin use regardless of
glycemic status to lower the risk of mortality and coronary
revascularization requirement based on the recommendations of
current guidelines.[8–11] However, limited studies have compared
long-term clinical outcomes of statin treatment between AMI
patients with prediabetes and those with DM who underwent
successful percutaneous coronary intervention (PCI) with newer-
generation DES. Here, we aimed to compare the 2-year major
clinical outcomes between these 2 groups.
2. Methods
2.1. Study population
This study enrolled patients from the Korea AMI Registry
(KAMIR).[14] The KAMIR is a prospective, observational, and
on-line registrywith amulticenter cohort study in SouthKorea that
was established in November 2005.[14] In the current study, we
attempted to confine to type 2 DM (T2DM) patients for diabetes.
We considered T2DM based on a previous study,[15] which
included patients from the KAMIR. In that study, T2DM was
defined by self-reported history (medical treatment, age at DM
onset [≥30years], andabsenceof a history of ketoacidosis).Hence,
we enrolled 23,391 AMI patients aged ≥30 years at the onset of
DM who underwent successful PCI with newer-generation DESs
from November 2005 to June 2015. Among them, patients with
incomplete laboratory results such as unidentified results of blood
hemoglobin (Hb)A1candbloodglucose (n=8432, 36%), patients
lost to follow-up (n=1069, 4.6%), and patients treated with first-
generation DES (n=1928, 8.2%) were excluded. Thus, a total of
11,962 AMI patients who underwent successful PCI with newer-
generationDESwere included. The types of newer-generationDES
used are listed inTable 1.The patientswere classifiedas statin users
(n=10,243, 85.6%) and statin nonusers (n=1719, 14.4%).
Thereafter, statin users and nonusers were further divided into the
normoglycemia (n=2708 [26.4%,groupA1]andn=372 [21.6%,
groupA2], respectively), prediabetes (n=3201 [31.3%, group B1]
and n=508 [29.6%, group B2], respectively), and T2DM (n=
4334 [42.3%, group C1] and n=839 [48.8%, group C2],
respectively) groups (Fig. 1, Table 1, Supplementary material 1,
http://links.lww.com/MD/F664). The main reasons for not using
statin among statin nonusers were as follows:
(1) expected risk was higher than benefit due to end-stage renal
failure, advanced age (≥75years), or severe heart failure (HF;
n=757, 44%);
(2) abnormal liver function (aspartate aminotransferase or
alanine aminotransferase level more than three-fold above
the upper normal limit; n=326, 19%);
(3) multiorgan failure (n=50, 2.9%);
(4) statin-induced myopathy or arthralgia (n=61, 3.5%); and
(5) unknown (n=525, 60.5%).
This study protocol was approved by the ethics committee at
each participating center and the Chonnam National University
Hospital Institutional Review Board (IRB) ethics committee
(CNUH-2011-172) according to the ethical guidelines of the
1975 Declaration of Helsinki. Informed consent was obtained
from all patients prior to their inclusion in the study.We followed
up all enrolled patients through face-to-face interview, phone
call, and chart review. All 11,962 patients completed a 2-year
clinical follow-up. All clinical events were evaluated by an
independent event adjudication committee. The processes of
event adjudication have been described previously by the KAMIR
investigators.[14]
2.2. Percutaneous coronary intervention and medical
treatments
Diagnostic coronary angiography and PCI were performed using
standard techniques.[16] Before PCI, all patients received loading
doses of aspirin (200–300mg) and other antiplatelet agents such
as clopidogrel (300–600mg), ticagrelor (180mg), or prasugrel
(60mg). After the index PCI, dual antiplatelet therapy (DAPT; a
combination of aspirin 100mg/day with clopidogrel 75mg/day,
ticagrelor 90mg twice daily, or prasugrel 5–10mg/day) was
recommended for at least 1year. Administration of triple
antiplatelet therapy (TAPT; cilostazol [100mg twice daily]
combined with DAPT) was based on individual operators’
discretion. The types and doses of statins prescribed as discharge
medications were as follows: atorvastatin (10–80mg), rosuvas-
tatin (5–40mg), simvastatin (10–40mg), pitavastatin (2–4mg),
pravastatin (5–40mg), and fluvastatin (40–80mg). The choice of
the type and dose of statin was left at the physicians’ discretion.
2.3. Study definitions and endpoints
Inclusion criteria for AMI were defined according to the current
guidelines.[8–11] A successful PCI was defined as a residual
stenosis of <30% and thrombolysis in myocardial infarction
grade 3 flow in the infarct-related artery (IRA) after the
procedure. Glycemic categories were determined based on the
glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG),
and random plasma glucose (RPG) levels of the patients at index
hospitalization as well as their medical history. T2DM was
defined as either known T2DM for which patients received
medical treatment (insulin or antidiabetics) or newly diagnosed
T2DM defined as an HbA1c level of ≥6.5%, a FPG of ≥126mg/
dL (7mmol/L), and/or RPG of ≥200mg/dL (11.1mmol/L)
according to the clinical practice recommendations of the
American Diabetes Association.[17] Prediabetes was defined as
anHbA1c of 5.7% to 6.4% and a FPG of 100 to 125mg/dL (5.6–
6.9mmol/L).[17] Additionally, the estimated glomerular filtration
rate (eGFR) was calculated using the Modification of Diet in
Renal Disease (MDRD) study equation.[18] The major clinical
outcome was the occurrence of major adverse cardiac events
(MACE), which were defined as all-cause death, recurrent
myocardial infarction (Re-MI), any repeat coronary revasculari-
zation. All-cause death was classified as cardiac death (CD) or
non-CD. Any repeat revascularization comprised target lesion
revascularization (TLR), target vessel revascularization (TVR),
Kim et al. Medicine (2021) 100:6 Medicine
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A1 vs B1 vs C1
Age (yr) 60.8±12.9 63.1±12.5 63.9±11.6 <.001 <.001 .003 <.001
Male, n (%) 2198 (81.2) 2428 (75.9) 3073 (70.9) <.001 <.001 <.001 <.001
LVEF (%) 53.3±10.3 53.1±10.6 51.5±11.4 .482 <.001 <.001 <.001
BMI (kg/m2) 23.9±3.0 24.2±3.2 24.4±3.1 <.001 <.001 .029 <.001
SBP (mm Hg) 132.0±27.6 129.9±26.9 131.6±27.6 .003 .527 .008 .006
DBP (mm Hg) 81.0±16.6 79.1±16.2 79.1±16.0 <.001 <.001 .917 <.001
STEMI, n (%) 1603 (59.2) 1903 (59.5) 2282 (52.7) .852 <.001 <.001 <.001
Primary PCI, n (%) 1546 (96.4) 1832 (96.3) 2185 (95.7) .783 .275 .394 .496
NSTEMI, n (%) 1105 (40.8) 1298 (40.5) 2052 (47.3) .852 <.001 <.001 <.001
PCI within 24h 979 (88.6) 1123 (86.5) 1752 (85.4) .125 .012 .358 .041
Cardiogenic shock, n (%) 100 (3.7) 133 (4.2) 179 (4.1) .384 .380 .953 .595
Hypertension, n (%) 1068 (39.4) 1398 (43.7) 2615 (60.3) .001 <.001 <.001 <.001
Dyslipidemia, n (%) 240 (8.9) 381 (11.9) 651 (15.0) <.001 <.001 <.001 <.001
Previous MI, n (%) 79 (2.9) 87 (2.7) 211 (4.9) .693 <.001 <.001 <.001
Previous PCI, n (%) 107 (4.0) 153 (4.8) 333 (7.7) .127 <.001 <.001 <.001
Previous CABG, n (%) 7 (0.3) 5 (0.2) 34 (0.8) .402 .005 <.001 <.001
Previous CVA, n (%) 114 (4.2) 160 (5.0) 343 (7.9) .154 <.001 <.001 <.001
Previous HF, n (%) 12 (0.4) 27 (0.8) 56 (1.3) .075 <.001 .074 .001
Current smokers, n (%) 1249 (46.1) 1521 (47.5) 1708 (39.4) .285 <.001 <.001 <.001
Peak CK-MB (mg/dL) 136.0±174.1 144.6±203.9 104.1±140.8 .079 <.001 <.001 <.001
Peak troponin-I (ng/mL) 48.3±74.1 48.1±114.4 47.2±136.9 .948 .666 .749 .858
NT-ProBNP (pg/mL) 1537.2±2973.8 1461.4±2164.4 2342.7±5662.3 .271 <.001 <.001 <.001
Hs-CRP (mg/dL) 6.9±26.4 8.9±48.7 9.5±39.1 .054 .001 .525 .026
Serum creatinine (mg/L) 1.00±0.99 1.03±1.49 1.19±1.68 .414 <.001 <.001 <.001
eGFR (mL/min/1.73m2) 92.3±38.3 90.4±39.9 85.1±41.7 <.001 <.001 <.001 <.001
Blood glucose (mg/L) 135.6±45.7 146.5±47.6 224.4±99.1 <.001 <.001 <.001 <.001
Hemoglobin A1c (%) 5.3±0.4 6.0±0.2 7.8±2.7 <.001 <.001 <.001 <.001
Total cholesterol (mg/dL) 182.6±40.0 190.8±42.9 180.4±48.1 <.001 .041 <.001 <.001
Triglyceride (mg/L) 119.5±87.7 135.1±107.3 152.1±130.5 <.001 <.001 <.001 <.001
HDL cholesterol (mg/L) 44.5±14.5 43.8±15.1 41.9±13.0 .070 <.001 <.001 <.001
LDL cholesterol (mg/L) 116.1±35.5 123.0±47.4 111.4±37.7 <.001 <.001 <.001 <.001
Discharge medications
Aspirin, n (%) 2689 (99.3) 3183 (99.4) 4308 (99.4) .499 .602 .832 .781
Clopidogrel, n (%) 2160 (79.8) 2712 (84.7) 3694 (85.2) <.001 <.001 .976 <.001
Ticagrelor, n (%) 358 (13.2) 310 (9.7) 386 (8.9) <.001 <.001 .260 <.001
Prasugrel, n (%) 180 (6.7) 165 (5.5) 228 (6.5) .017 .016 .875 .021
Cilostazole, n (%) 378 (14.0) 615 (19.2) 877 (20.2) <.001 <.001 .271 <.001
BBs, n (%) 2326 (85.9) 2752 (86.0) 3771 (87.0) .930 .181 .192 .293
ACEIs, n (%) 1628 (60.1) 1877 (58.6) 2209 (53.3) .248 <.001 <.001 <.001
ARBs, n (%) 656 (24.2) 798 (24.9) 1341 (30.9) .567 <.001 <.001 <.001
CCBs, n (%) 142 (5.2) 171 (5.3) 327 (7.5) .866 <.001 <.001 <.001
Statin, n (%)
Atorvastatin, n (%) 1324 (48.9) 1480 (46.2) 2184 (50.4) .042 .221 <.001 .002
Rosuvastatin, n (%) 1033 (38.1) 1285 (40.1) 1495 (34.5) .117 .002 <.001 <.001
Simvastatin, n (%) 179 (6.6) 194 (6.1) 265 (6.1) .387 .405 .923 .629
Pitavastatin, n (%) 128 (4.7) 203 (6.3) 313 (7.2) .008 <.001 .140 <.001
Pravastatin, n (%) 34 (1.3) 33 (1.0) 62 (1.4) .460 .598 .144 .307
Fluvastatin, n (%) 10 (0.4) 6 (0.2) 15 (0.3) .213 .841 .269 .354
Diabetes management
Diet, n (%) 348 (8.0)
Oral agent, n (%) 2687 (62.0)
Insulin, n (%) 241 (5.6)
Untreated, n (%) – 1058 (24.4)
Infarct-related artery
Left main, n (%) 48 (1.8) 47 (1.5) 82 (1.9) .406 .785 .178 .370
LAD, n (%) 1379 (50.9) 1589 (49.6) 1991 (45.9) .305 <.001 .001 <.001
LCx, n (%) 446 (17.4) 533 (16.8) 721 (16.6) .852 .855 .986 .979
RCA, n (%) 835 (30.8) 1032 (32.2) 1540 (35.5) .247 <.001 .003 <.001
Treated vessel
Left main, n (%) 72 (2.7) 88 (2.7) 130 (3.0) .872 .420 .522 .665
LAD, n (%) 1616 (59.7) 1894 (59.2) 2538 (58.6) .693 .355 .596 .642
LCx, n (%) 676 (25.0) 833 (26.0) 1208 (27.9) .352 .007 .075 .020
RCA, n (%) 984 (36.3) 1244 (38.9) 1876 (43.3) .046 <.001 <.001 <.001
ACC/AHA lesion type
Type B1, n (%) 342 (12.6) 421 (13.2) 527 (12.2) .550 .560 .199 .438
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A1 vs B1 vs C1
Type B2, n (%) 934 (34.5) 1012 (31.6) 1442 (33.3) .019 .293 .129 .061
Type C, n (%) 1228 (43.9) 1449 (42.7) 2007 (46.3) .951 .431 .370 .600
Extent of CAD
Single-vessel, n (%) 1501 (55.4) 1686 (52.7) 1867 (43.1) .037 <.001 <.001 <.001
Two-vessel, n (%) 804 (29.7) 981 (30.6) 1449 (33.4) .425 .001 .011 .002
≥Three-vessel, n (%) 403 (14.9) 534 (16.7) 1018 (23.5) .059 <.001 <.001 <.001
IVUS, n (%) 573 (21.2) 783 (24.5) 938 (21.6) .003 .655 .004 .003
OCT, n (%) 21 (0.8) 28 (0.9) 31 (0.7) .774 .776 .509 .739
FFR, n (%) 28 (1.0) 45 (1.4) 60 (1.4) .237 .225 .938 .365
Drug-eluting stents
∗
ZES, n (%) 842 (31.1) 1099 (34.3) 1480 (34.1) .008 .008 .868 .012
EES, n (%) 1402 (51.8) 1655 (51.7) 2259 (52.1) .957 .775 .718 .926
BES, n (%) 472 (17.4) 449 (14.0) 575 (13.3) <.001 <.001 .341 <.001
Others, n (%) 51 (1.9) 68 (2.1) 108 (2.5) .517 .099 .316 .220
Stent diameter (mm) 3.15±0.42 3.14±0.41 3.10±0.42 .203 <.001 <.001 <.001
Stent length (mm) 27.4±11.5 27.1±11.5 27.8±11.9 .294 .172 .010 .033
Number of stent 1.43±0.74 1.48±0.79 1.56±0.83 .004 <.001 <.001 <.001
Values are means±SD or numbers and percentages. The P values for categorical data were obtained from the chi-square or Fisher’s exact test. For continuous variables, differences among the 3 groups were
evaluated using the analysis of variance or the Jonckheere–Terpstra test, and post-hoc analysis between the 2 groups was carried out using the Hochberg test or Dunnett-T3 test.
ACC/AHA=American College of Cardiology/American Heart Association, ACEIs= angiotensin converting enzyme inhibitors, ARBs=angiotensin receptor blockers, BBs=beta-blockers, BES=biolimus-eluting
stent, BMI=body mass index, CABG= coronary artery bypass graft, CAD= coronary artery disease, CCBs=calcium channel blockers, CK-MB= creatine kinase myocardial band, CPR= cardiopulmonary
resuscitation, CVA= cerebrovascular events, DBP=diastolic blood pressure, EES= everolimus-eluting stent, eGFR= estimated glomerular filtration rate, FFR= fractional flow reserve, HDL=high-density
lipoprotein, HF=heart failure, hs-CRP=high-sensitivity C-reactive protein, IVUS= intravascular ultrasound, LAD= left anterior descending coronary artery, LCx= left circumflex coronary artery, LDL= low-
density lipoprotein, LVEF= left ventricular ejection fraction, MI=myocardial infarction, NSTEMI=non-ST-segment elevation myocardial infarction, NT-ProBNP=N-terminal pro-brain natriuretic peptide, OCT=
optical coherence tomography, PCI=percutaneous coronary intervention, RCA= right coronary artery, SBP= systolic blood pressure, STEMI=ST-segment elevation myocardial infarction, T2DM= type 2
diabetes mellitus, ZES= zotarolimus-eluting stent.
∗
Drug-eluting stents were composed of ZES (Resolute Integrity stent; Medtronic, Inc., Minneapolis, MN), EES (Xience Prime stent, Abbott Vascular, Santa Clara, CA; or Promus Element stent, Boston Scientific,
Natick, MA), and BES (BioMatrix Flex stent, Biosensors International, Morges, Switzerland; or Nobori stent, Terumo Corporation, Tokyo, Japan).
A total of 23,391 AMI patients aged ≥ 30 years at the onset of diabetes, who underwent 
successful DESs implantation from November 2005 to June 2015 in the KAMIR
Exclusion
- Incomplete laboratory results including unidentified             
results of blood HbA1c and blood glucose (n = 8,432)
- Lost to follow-up (n = 1,069)
- First-generation DESs (n = 1,928)
Finally, a total of 11,962 patients with AMI who underwent successful implantation of 
newer-generation DESs were included







Group C1 Group A2 Group B2 Group C2







Figure 1. Flow chart. AMI= acute myocardial infarction, DESs= drug-eluting stents, KAMIR = Korea AMI Registry, NG = normoglycemia, T2DM = type 2 diabetes
mellitus.
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and non-TVR. The definitions of Re-MI, TLR, TVR, and non-
TVR have been published previously.[19]
2.4. Statistical analysis
For continuous variables, differences among the 3 groups were
evaluated using analysis of variance or the Jonckheere–Terpstra
test, whereas a post-hoc analysis of the 2 groups was performed
using the Hochberg test or Dunnett T3 test. Data are expressed as
means± standard deviation. The chi-square test or Fisher’s exact
test was performed, as appropriate, to analyze intergroup
differences for categorical variables. Data are expressed as
numbers and percentages. Various clinical outcomes were
analyzed using the Kaplan–Meier method and were compared
among the 3 groups using the log-rank test. Because the
differences in baseline characteristic could significantly affect
major clinical outcomes, sensitivity analyses were performed to
adjust for confounders. A multivariate Cox regression model was
used. Before multivariate Cox regression analysis, univariate
analysis was performed. Covariates included in univariate model
were selected if they were significantly different among the 3
groups (P< .001), which are listed in Supplementary material 2,
http://links.lww.com/MD/F665 and 3, http://links.lww.com/MD/
F666. Any variable with P value of <.001 in univariate analysis
and conventional risk factors of poor outcomes in the AMI
population were considered potential confounding factors and
were entered into the multivariate analysis. Variables included in
the multivariate analysis were as follows: age; male sex; left
ventricular ejection fraction (LVEF); body mass index; ST-
segment elevation myocardial infarction (STEMI); hypertension;
dyslipidemia; a previous history of MI, PCI, coronary artery
bypass grafting (CABG), and cardiovascular accidents; current
smoker; serum creatinine level; eGFR; total cholesterol level;
triglyceride level; high-density lipoprotein cholesterol level; low-
density lipoprotein cholesterol level; discharge medications
(clopidogrel, ticagrelor, angiotensin-converting enzyme inhib-
itors [ACEIs], angiotensin receptor blockers [ARBs], rosuvasta-
tin, and pitavastatin); IRA (left anterior descending artery
[LAD]); treated vessel (right coronary artery [RCA]); single-
vessel disease and ≥three-vessel disease; diameter of placed stent;
and the number of stents placed. The assumption of proportion-
ality was assessed graphically by the log-minus-log plot, and Cox
proportional hazard models for all clinical outcomes satisfied the
proportional hazards assumption. Moreover, to identify inde-
pendent predictors of MACE and all-cause death, we used
multivariate Cox proportional hazard model. C-statistics with
95% confidence interval (CI) were calculated to validate the
discriminant function of the model. All probability values were
two-sided and P value of <.05 was considered statistically
significant for all analyses. All statistical analyses were performed




The mean LVEF value in our study population was >50%
(Table 1). The baseline characteristics of Group A1 (normogly-
cemia and statin users) are as follows: largest number of men and
patients with one-vessel disease; highest prescription rate of
ticagrelor, prasugrel, and ACEIs; and highest number of cases
with LAD as IRA and BES as the deployed stent and deployed
stents with the largest diameter. The baseline characteristics of
Group B1 (prediabetes and statin users) are as follows: highest
number of current smokers and cases with STEMI; highest levels
of total and low-density lipoprotein (LDL) cholesterols and peak
creatine kinase-MB (CK-MB) level; highest prescription rate of
rosuvastatin; and highest use of intravascular ultrasound and
zotarolimus-eluting stent (ZES) as the deployed stent. The
baseline characteristics of Group C1 (diabetes and statin users)
are as follows: patients with the oldest mean age; highest number
of cases with non-STEMI (NSTEMI) and patients with multi-
vessel disease and a previous history of hypertension, dyslipide-
mia, PCI, CABG, and HF; highest levels of N-terminal pro-brain
natriuretic peptide, serum creatinine, and triglyceride; highest
prescription rate of clopidogrel, ARBs, and atorvastatin; highest
number of cases with RCA as IRA and treated vessel; longest
length of deployed stents; and highest number of deployed stents.
The comparison of baseline characteristics between statin users
and nonusers is presented in Supplementary material 1, http://
links.lww.com/MD/F664. The baseline characteristics of statin
nonusers are presented in Supplementary material 4, http://links.
lww.com/MD/F667.
3.2. Clinical outcomes
The comparisons of clinical outcomes among the 3 glycemic
groups during the 2-year follow-up period are presented in
Tables 2 and 3 and Figure 2. In statin users, the cumulative
incidences of MACE (adjusted hazard ratio [aHR]: 1.095; 95%
CI: 0.918–1.306; P= .314), all-cause death, CD, and any repeat
revascularization were similar between group B1 (prediabetes)
and C1 (T2DM) (Table 2). The cumulative incidences of MACE
(aHR: 1.288; 95% CI: 1.033–1.606; P= .025) and all-cause
death (aHR: 1.525; 95% CI: 1.024–2.271; P= .038) were higher
in group B1 than in group A1 (Table 2). The cumulative
incidences of MACE (aHR: 1.402; 95% CI: 1.139–1.727;
P= .001), all-cause death (aHR: 1.642; 95% CI: 1.130–2.385;
P= .009), and CD (aHR: 1.574; 95% CI: 1.004–2.472; P= .048)
were significantly higher in group C1 than in group A1 (Table 2).
In statin nonusers, the cumulative incidences of MACE, all-cause
death, CD, and any repeat revascularization were similar
between A2 and B2 as well as between B2 and C2 (Table 2).
However, the cumulative incidences of all-cause death (aHR:
1.500; 95% CI: 1.017–2.212; P= .041), CD (aHR: 1.631; 95%
CI: 1.052–2.543; P= .030), and any repeat revascularization
(aHR: 2.068; 95% CI: 1.066–4.012; P= .040) were higher in
group C2 than in group C1 (Table 2). In all the 3 groups
(normoglycemia, prediabetes, and T2DM), statin treatment
reduced the cumulative incidences of MACE, all-cause death,
and CD (Table 3). Additionally, in the T2DM group, the
cumulative incidence of any repeat revascularization was lower
among statin users than among statin nonusers (aHR: 1.705;
95% CI: 1.218–2.395; P= .002) (Table 3). Kaplan–Meier
analyses for major clinical outcomes among statin nonusers
are presented in Supplementary material 5, http://links.lww.com/
MD/F668. Independent predictors forMACE and all-cause death
among statin users at 2years are listed in Table 4. Male sex,
decreased LVEF (<40%), decreased eGFR (<60mL/minute/1.73
m2), ACEI, and ≥three-vessel disease were found to be
meaningful independent predictors for MACE. Moreover, old
age (≥65years), decreased LVEF, decreased eGFR, BBs, ACEIs,
American College of Cardiology/American Heart Association
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(ACC/AHA) type B2/C lesions, and ≥three-vessel disease were
found to be independent predictors for all-cause death.
4. Discussion
In this study, clinical outcomes of 2-year statin treatment were
compared between AMI patients with prediabetes and those with
T2DM treated with the newer-generation DES to determine
differences in long-term outcomes between both the groups. In
this retrospective, observational registry study, analysis of statin
treatment outcomes revealed the following:
(1) the cumulative incidences of MACE, all-cause death, CD, Re-
MI, and any repeat revascularization were similar between
the prediabetes and T2DM groups;
Table 2





Prediabetes Log-rank Unadjusted HR (95% CI) P Adjusted
∗
HR (95% CI) P
MACE 129 (5.4) 206 (6.9) .015 1.314 (1.054–1.637) .015 1.288 (1.033–1.606) .025
All-cause death 37 (1.5) 71 (2.4) .023 1.580 (1.062–2.352) .024 1.525 (1.024–2.271) .038
Cardiac death 26 (1.0) 51 (1.7) .041 1.627 (1.014–2.609) .043 1.540 (0.959–2.473) .074
Re-MI 37 (1.6) 52 (1.7) .498 1.157 (0.759–1.764) .498 1.186 (0.776–1.811) .430




T2DM Log-rank Unadjusted HR (95% CI) P Adjusted
∗
HR (95% CI) P
MACE 129 (5.4) 360 (9.1) <.001 1.704 (1.394–2.084) <.001 1.402 (1.139–1.727) .001
All-cause death 37 (1.5) 144 (3.6) <.001 2.372 (1.653–3.405) <.001 1.642 (1.130–2.385) .009
Cardiac death 26 (1.0) 96 (2.4) <.001 2.261 (1.466–3.488) <.001 1.574 (1.004–2.472) .048
Re-MI 37 (1.6) 99 (2.6) .012 1.612 (1.105–2.352) .013 1.473 (0.985–2.189) .052




T2DM Log-rank Unadjusted HR (95% CI) P Adjusted
∗
HR (95% CI) P
MACE 206 (6.9) 360 (9.1) .002 1.302 (1.097–1.545) .003 1.095 (0.918–1.306) .314
All-cause death 71 (2.4) 144 (3.6) .004 1.508 (1.135–2.003) .005 1.099 (0.819–1.475) .530
Cardiac death 51 (1.7) 96 (2.4) .052 1.397 (0.995–1.962) .053 1.029 (0.723–1.464) .873
Re-MI 52 (1.7) 99 (2.6) .040 1.418 (1.014–1.983) .041 1.272 (0.902–1.795) .170





Prediabetes Log-rank Unadjusted HR (95% CI) P Adjusted† HR (95% CI) P
MACE 51 (14.0) 79 (15.8) .484 1.134 (0.797–1.612) .485 1.242 (0.869–1.775) .234
All-cause death 34 (9.3) 57 (11.3) .334 1.232 (0.806–1.884) .336 1.391 (0.905–2.140) .133
Cardiac death 26 (7.1) 51 (10.1) .126 1.442 (0.899–2.531) .129 1.423 (0.892–2.401) .142
Re-MI 6 (1.8) 10 (2.1) .697 1.222 (0.444–3.363) .698 1.079 (0.385–3.021) .886




T2DM Log-rank Unadjusted HR (95% CI) P Adjusted† HR (95% CI) P
MACE 51 (14.0) 153 (18.5) .063 1.349 (0.983–1.852) .064 1.380 (1.001–1.903) .050
All-cause death 34 (9.3) 113 (13.6) .038 1.495 (1.019–2.194) .040 1.500 (1.017–2.212) .041
Cardiac death 26 (7.1) 94 (11.3) .027 1.624 (1.052–2.507) .029 1.631 (1.052–2.543) .030
Re-MI 6 (1.8) 24 (3.2) .189 1.805 (0.738–4.415) .193 1.915 (0.775–4.732) .159




T2DM Log-rank Unadjusted HR (95% CI) P Adjusted† HR (95% CI) P
MACE 79 (15.8) 153 (18.5) .210 1.189 (0.906–1.560) .211 1.051 (0.796–1.388) .725
All-cause death 57 (11.3) 113 (13.6) .237 1.211 (0.881–1.665) .239 1.006 (0.726–1.394) .971
Cardiac death 51 (10.1) 94 (11.3) .500 1.124 (0.799–1.581) .501 1.092 (0.984–1.623) .103
Re-MI 10 (2.1) 24 (3.2) .295 1.479 (0.707–3.093) .298 1.573 (0.741–3.344) .238
Any repeat revascularization 22 (4.9) 48 (6.6) .242 1.350 (0.815–2.236) .244 1.269 (0.758–2.124) .365
ACEIs= angiotensin-converting enzyme inhibitors, ARBs= angiotensin receptor blockers, BMI=body mass index, CABG= coronary artery bypass graft, CI= confidence interval, CVA= cerebrovascular
accidents, eGFR= estimated glomerular filtration rate, HDL=high-density lipoprotein, HR=hazard ratio, IRA= infarct-related artery, LAD= left anterior descending artery, LDL= low-density lipoprotein, LVEF=
left ventricular ejection fraction, MACE=major adverse cardiac events, PCI=percutaneous coronary intervention, RCA= right coronary artery, Re-MI= recurrent myocardial infarction, STEMI=ST-segment
elevation myocardial infarction, T2DM= type 2 diabetes mellitus.
∗
Adjusted by age, male, LVEF, BMI, STEMI, hypertension, dyslipidemia, previous history of MI, PCI, CABG, CVA, current smoker, serum creatinine, eGFR, total cholesterol, triglyceride, HDL-cholesterol, LDL-
cholesterol, discharge medications (clopidogrel, ticagrelor, ACEIs, ARBs, rosuvastatin, pitavastatin), IRA (LAD), treated vessel (RCA), single-vessel disease, ≥three-vessel disease, stent diameter, and number of
stent.
† Adjusted by age, male, STEMI, hypertension, dyslipidemia, serum creatinine, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, ≥three-vessel disease, stent diameter.
Kim et al. Medicine (2021) 100:6 Medicine
6
(2) the cumulative incidences ofMACE and all-cause death in the
prediabetes group and those of MACE, all-cause death, and
CD in the T2DM group were higher than those in the
normoglycemia group;
(3) the cumulative incidences of MACE, all-cause death, and CD
in all the 3 glycemic groups (normoglycemia, prediabetes, and
T2DM) of statin users were lower than those of statin
nonusers;
(4) decreased LVEF, decreased eGFR, ACEIs, and ≥three-vessel
disease were common independent predictors of both MACE
and all-cause death.
Statin can show beneficial effect on primary and secondary
prevention of adverse cardiovascular events by inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
activity.[20,21] These cardioprotective effects of statin are
characterized by the prevention of myocardial necrosis, myocar-
dial fibrosis, and cardiac remodeling through the anti-inflamma-
tory, enhanced endothelial nitric oxide production, and anti-
oxidative actions.[22,23] In this study, decreased cumulative
incidences of MACE, all-cause death, and CD were noted among
statin users of all the 3 glycemic groups (Table 3). These results
are comparable to those of previous reports.[12,19,24,25] These
results demonstrated obviously positive relationship of statin
treatment with longer survival and longer MACE-free survival
among AMI patients regardless of glycemic status in the era of
newer-generation DES. Early initiation of statin treatment before
discharge reduces the rates of MI and total mortality at 1-year in
patients with acute coronary syndrome (ACS).[19,25] Moreover,
early statin treatment induces stabilization of atherosclerotic
vulnerable plaque and reduces new plaque development after
ACS.[26,27] However, despite statin treatment, the cumulative
incidences of MACE (aHR: 1.402; 95% CI: 1.139–1.727;
P= .001), all-cause death (aHR: 1.642; 95% CI: 1.130–2.385;
P= .009), and CD (aHR: 1.574; 95% CI: 1.004–2.472; P= .048)
were significantly higher in the T2DM group than in the
normoglycemia group (Table 2). Hyperglycemia accelerates the
formation of advanced glycation end products (AGEs) by
nonenzymatic glycation reactions.[28] These AGEs may play
important roles in the development of coronary artery disease
both independently and synergistically with DM.[29] Shimomura
et al[30] demonstrated that the serum level of glyceraldehyde-
derived AGEs was significantly (P< .05) suppressed in AMI
patients after 2weeks of atorvastatin therapy (initial dose of 40
mg at admission followed by a maintenance dose of 10mg/day)
compared with that in the control group. Another report[31]
suggested that statin is one of the most recent promising anti-
AGEs agents in DM. However, the effects of statin treatment in
terms of long-term clinical outcomes in AMI patients with
prediabetes are not well established.
In this study, both in the prediabetes and T2DM groups, the
aHRs for major clinical outcomes were not significantly different
regardless of the use of statin (Table 2). In the statin users, both in
the prediabetes and T2DM groups, the higher cumulative
incidence of MACE compared with normoglycemia group may
Table 3





Group A2 Log-rank Unadjusted HR (95% CI) P Adjusted
∗
HR (95% CI) P
Normoglycemia
MACE 129 (5.4) 51 (14.0) <.001 2.863 (2.070–3.961) <.001 2.146 (1.507–3.057) <.001
All-cause death 37 (1.5) 34 (9.3) <.001 6.682 (4.193–10.65) <.001 3.468 (2.051–5.860) <.001
Cardiac death 26 (1.0) 26 (7.1) <.001 7.330 (4.255–12.63) <.001 3.391 (1.826–6.230) <.001
Re-MI 37 (1.6) 6 (1.8) .735 1.160 (0.490–2.750) .736 1.094 (0.446–2.683) .844




Group B2 Log-rank Unadjusted HR (95% CI) P Adjusted† HR (95% CI) P
Prediabetes
MACE 206 (6.9) 79 (15.8) <.001 2.474 (1.909–3.207) <.001 2.054 (1.563–2.698) <.001
All-cause death 71 (2.4) 57 (11.3) <.001 5.180 (3.655–7.340) <.001 3.270 (2.254–4.742) <.001
Cardiac death 51 (1.7) 51 (10.1) <.001 6.453 (4.377–9.514) <.001 3.902 (2.582–5.897) <.001
Re-MI 52 (1.7) 10 (2.1) .537 1.237 (0.629–2.435) .537 1.253 (0.623–2.520) .526




Group C2 Log-rank Unadjusted HR (95% CI) P Adjusted‡ HR (95% CI) P
T2DM
MACE 360 (9.1) 153 (18.5) <.001 2.264 (1.874–2.735) <.001 1.662 (1.358–2.035) <.001
All-cause death 144 (3.6) 113 (13.6) <.001 4.188 (3.273–5.358) <.001 2.346 (1.791–3.072) <.001
Cardiac death 96 (2.4) 94 (11.3) <.001 5.218 (3.926–6.935) <.001 2.584 (1.888–3.536) <.001
Re-MI 99 (2.6) 24 (3.2) .290 1.272 (0.814–1.987) .291 1.123 (0.705–1.788) .626
Any revascularization 149 (3.8) 48 (6.6) .001 1.719 (1.242–2.380) .001 1.705 (1.218–2.395) .002
ACC/AHA=American College of Cardiology/American Heart Association, ACEIs=angiotensin converting enzyme inhibitors, BBs=beta-blockers, BES=biolimus-eluting stents, CI= confidence interval, DBP=
diastolic blood pressure, eGFR= estimated glomerular filtration rate, HDL=high-density lipoprotein, HR=hazard ratio, LDL= low-density lipoprotein, LVEF= left ventricular ejection fraction, MACE=major
adverse cardiac events, PCI=percutaneous coronary intervention, Re-MI= recurrent myocardial infarction, SBP= systolic blood pressure, T2DM= type 2 diabetes mellitus.
∗
Adjusted by age, male, SBP, blood glucose, eGFR, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, aspirin, clopidogrel, ticagrelor, BBs, ACEIs, BES, stent length.
† Adjusted by age, male, LVEF, eGFR, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, aspirin, clopidogrel, ticagrelor, prasugrel, ACC/AHA type C lesion, BES, stent length.
‡ Adjusted by age, male, LVEF, DBP, PCI within 24h, cardiogenic shock, total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, aspirin, clopidogrel, ticagrelor, BBs, ACEIs, stent length.
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Figure 2. Kaplan–Meier analysis for the MACE (A), all-cause death (B), cardiac death (C), Re-MI (D), and any repeat revascularization (E) in statin users. MACE=
major adverse cardiac events, Re-MI= recurrent myocardial infarction, T2DM= type 2 diabetes mellitus.
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be related with higher cumulative incidence of all-cause death
(prediabetes) or all-cause death and CD (T2DM group).
However, the cumulative incidences of all-cause death or CD
were statistically insignificantly different between these 2
groups (Table 2).
Compared with normoglycemia, chronically elevated glucose
leads to pan-vascular damage (i.e., macro- and micro-anigopathy
through oxidation and vascular inflammation) and therefore,
vascular damage is present in the prediabetic state, and its severity
is associated with the time of hyperglycemia onset.[32,33] The time
spent waiting for hyperglycemia to reach the currently accepted
cut-off levels for the diagnosis of T2DM and to intervene may
allow vascular damage to advance and become irreversible.[34]
Although some studies have reported conflicting findings,[3–6] in
the Biodegradable Polymer and Durable Polymer Drug-eluting
Stents in an All Comers Population (BIO-RESORT) Silent
Diabetes Study,[35] the cumulative incidence of MACE was
different between patients with prediabetes (5.5%) and normo-
glycemia (3%; log-rank, P= .07). In our study, aHR for MACE
was significantly higher in the prediabetes group than in the
normoglycemia group (aHR: 1.288; 95% CI: 1.033–1.606;
P= .025; Table 2). In another sub-study of the BIO-RESOT trial,
clinical outcomes were similar between patients with prediabetes
and those with DM (11.1% vs 10.5%).[3] In addition, other
study[36] has suggested that the cumulative incidences of MACE,
all-cause death, CD, and any repeat revascularization were
similar between AMI patients with prediabetes and those with
T2DM after the RASI therapy. In our study, statin reduced the
rate of any repeat revascularization in the T2DM group, with an
aHR of 1.159 (group A1 vs C1; 95% CI: 0.862–1.557; P= .329)
among statin users compared with 2.068 (group A2 vs C2; 95%
CI: 1.066–4.012; P= .040) among statin nonusers (Table 2). This
result is comparable with that of the Zhang et al study.[37] In their
multicenter, prospective cohort study, after propensity-score
matching, post-discharge statin treatment significantly lowered
the risk of repeat revascularization (HR: 0.74; 95% CI: 0.56–
1.00; P= .005) in 2737 patients who underwent PCI. In Table 2,
the occurrenceMACEwas significantly higher in prediabetes and
T2DM groups compared with normoglycemia group who
received statin treatment. Therefore, although statin treatment
reduced the occurrence of MACE, all-cause death, and CD
compared with statin nonusers regardless of glycemic status
(Table 3), the beneficial effect of statin treatment could be some
different according to glycemic status. Hence, hyperglycemic
status may be more related to poor clinical outcomes than with
normoglycemia after statin treatment. However, this hypothesis
is likely to be proved by further studies.
Despite the beneficial effects of statin, previous studies reported
an increased risk of developing new-onset DM after long-term
statin treatment.[38,39] However, because this information was
not included in the KAMIR data, we could not present the
cumulative events of statin-related new-onset DM during the
follow-up period. This point is a major weakness of this study.
Although the study population was insufficient to draw
conclusions, more than 50 high-volume university or community
hospitals of South Korea participated in this study.Moreover, the
population with prediabetes is an important and a common
population visiting interventional cardiologists.[40] Hence, we
believe that our study can provide useful information to
interventional cardiologists, performing PCI with newer-genera-
tion DES in AMI patients, regarding the importance of
prediabetes and the relationship of prediabetes with worse
cardiovascular outcomes after statin treatment.
This study has several limitations. First, although blood
cholesterol levels, especially LDL-cholesterol level, are important
during the follow-up period, we could not provide these values
due to the limitation of this registry data. Second, to increase the
diagnostic accuracy of prediabetes, oral glucose tolerance test
Table 4
Independent predictors for MACE and all-cause death in statin users at 2yr.
MACE All-cause death
Variables Unadjusted HR (95% CI) P Adjusted HR (95% CI) P Unadjusted HR (95% CI) P Adjusted HR (95% CI) P
Group A1 vs Group B1 1.314 (1.054–1.637) .015 1.292 (1.033–1.615) .025 1.580 (1.062–2.352) .024 1.519 (1.015–2.274) .042
Group A1 vs Group C1 1.704 (1.394–2.084) <.001 1.397 (1.131–1.727) .002 2.372 (1.653–3.405) <.001 1.584 (1.085–2.312) .017
Group B1 vs Group C1 1.302 (1.097–1.545) .003 1.072 (0.896–1.283) .445 1.508 (1.135–2.003) .005 1.097 (0.814–1.479) .544
Age, ≥65yr 1.423 (1.226–1.651) <.001 1.053 (0.886–1.252) .556 2.622 (2.013–3.416) <.001 1.725 (1.277–2.329) <.001
Male sex 1.439 (1.227–1.688) <.001 1.313 (1.092–1.579) .004 1.659 (1.282–2.148) <.001 1.258 (0.940–1.685) .123
STEMI 1.261 (1.086–1.463) .002 1.153 (0.989–1.343) .068 1.432 (1.119–1.834) .004 1.225 (0.950–1.579) .117
LVEF, <40% 2.079 (1.727–2.502) <.001 1.795 (1.483–2.172) <.001 3.317 (2.527–4.355) <.001 2.443 (1.841–3.242) <.001
Hypertension 1.346 (1.159–1.564) <.001 1.087 (0.925–1.278) .309 1.680 (1.302–2.167) <.001 1.108 (0.843–1.456) .461
Dyslipidemia 1.169 (0.944–1.447) .153 1.133 (0.913–1.407) .258 1.182 (0.831–1.682) .352 1.172 (0.820–1.676) .385
Current smokers 1.265 (1.086–1.474) .003 1.037 (0.869–1.237) .686 1.731 (1.327–2.259) <.001 1.055 (0.780–1.428) .758
Total cholesterol 0.997 (0.995–0.998) <.001 0.998 (0.995–1.001) .113 0.995 (0.992–0.998) <.001 0.998 (0.994–1.002) .338
Triglyceride 0.999 (0.998–1.000) .013 1.000 (0.999–1.000) .301 0.999 (0.998–1.000) .138 1.000 (0.999–1.002) .663
HDL-cholesterol 0.997 (0.991–1.003) .287 0.998 (0.992–1.005) .625 0.994 (0.984–1.005) .286 0.998 (0.988–1.008) .658
LDL-cholesterol 0.997 (0.995–0.999) .015 1.001 (0.998–1.003) .685 0.995 (0.992–0.999) .007 1.000 (0.996–1.004) .820
eGFR, <60mL/min/1.73m2 1.692 (1.426–2.007) <.001 1.353 (1.128–1.622) .001 3.163 (2.456–4.075) <.001 2.078 (1.582–2.730) <.001
BBs 1.319 (1.081–1.610) .006 1.146 (0.935–1.403) .190 1.997 (1.492–2.673) <.001 1.530 (1.135–2.062) .005
ACEIs 1.423 (1.227–1.652) <.001 1.335 (1.146–1.555) <.001 1.879 (1.463–2.412) <.001 1.582 (1.224–2.045) <.001
ACC/AHA type B2/C lesion 1.164 (0.966–1.403) .110 1.158 (0.957–1.400) .131 1.425 (1.023–1.985) .036 1.419 (1.012–1.988) .042
≥Three-vessel disease 1.937 (1.651–2.272) <.001 1.724 (1.463–2.032) <.001 2.028 (1.560–2.638) <.001 1.557 (1.187–2.042) .001
Stent diameter<3.0mm 1.093 (0.931–1.283) .276 1.040 (0.882–1.225) .642 1.041 (0.792–1.368) .774 1.282 (0.970–1.695) .081
Stent length≥30mm 1.165 (0.995–1.365) .058 1.058 (0.900–1.243) .488 1.399 (1.084–1.807) .010 1.179 (0.908–1.532) .217
ACC/AHA=American College of Cardiology/American Heart Association, BB=beta-blockers, CI= confidence interval, eGFR= estimated glomerular filtration rate, HDL=high-density lipoprotein, HR=hazard
ratio, LDL= low-density lipoprotein, LVEF= left ventricular ejection fraction, MACE=major adverse cardiac events, STEMI=ST-elevation myocardial infarction.
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should be performed. However, we defined prediabetes by the
HbA1c and FPG levels, which is an important bias. Third, there
may have been some under-reporting and/or missed data due to
the non-randomized nature of this study. Fourth, this study was
based on discharge medication data and we could not obtain
precise information regarding participants’ adherence or non-
adherence to antidiabetic drugs during the follow-up period. This
might constitute an additional bias. Fifth, statins show their effect
in longer duration of use. Even though this study included
patients from November 2005 to June 2015, the follow-up
duration of the individual patient was strictly confined to 2 years
after discharge. Therefore, the 2-year follow-up period of this
study was relatively short for determining long-term major
clinical outcomes and the sample size was not adequate enough to
reach a conclusion. Sixth, although multivariate analysis was
performed to strengthen our results, variables not included in the
KAMIR may act as a bias. Finally, unfortunately, this registry
data did not include complete information concerning the
presence or absence of change in any prescription dose of each
statin and long-term drug compliance, and drug-related adverse
events during the follow-up period. Hence, we could not provide
results separately for the different statins, inevitably.
To conclude, in the era of newer-generation DES, this
retrospective, observational registry study revealed that AMI
patients with prediabetes had worse clinical outcomes than those
with normoglycemia and comparable to those with T2DM after
2-year statin treatment. However, further studies are warranted
to confirm the current findings.
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